Loading stock data…
BCRX
$8.33-0.10 (-1.19%)
After Hours$8.49+0.16 (+1.92%)· Last close Jun 9
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioCryst Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.33. Wall Street consensus targets $21.30 (10 analysts), implying a +155.7% move over the next 12 months. The stock is currently 26% below its 52-week high of $11.22, remaining 5.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +155.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$8.33
Potential Downside
0%
Whystock Fair Value$8.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$21.30+155.7%
Range$13.00 – $32.00
Fundamentals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
82.69%
Volume
Today's trading volume
3.80M
Recent News
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?
BioCryst Pharmaceuticals reported first-quarter 2026 results with revenue of US$156.41 million, up from US$145.53 million a year earlier, but moved from a small profit to a net loss of US$721.81 million, while maintaining full‑year revenue guidance of US$635 million to US$660 million. Alongside these results, the company entered a licensing agreement giving an Irish affiliate of Neopharmed Gentili exclusive European rights to navenibart for hereditary angioedema, bringing in US$70 million...
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal
BioCryst Pharmaceuticals (BCRX) is back in focus after first quarter results combined higher revenue with a very large reported loss, alongside a fresh licensing deal for navenibart in Europe and reaffirmed full year revenue guidance. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $8.58, BioCryst’s 90 day share price return of 30.99% and year to date gain of 14.40% contrast with a decline of 17.02% in the 1 year total shareholder return. This suggests that momentum...
BioCryst (BCRX) Q1 2026 Earnings Transcript
2026 is off to a very good start for BioCryst, marked by strong execution on our commercial and development programs, the smooth integration of Astria Therapeutics and disciplined management of our finances. ORLADEYO net revenue of $148.3 million for the quarter was right in line with our expectations, and monthly new patient prescriptions have tracked slightly ahead of 2025 averages. The pediatric launch -- pediatric indication launch is just beginning, but early signals confirm the need for oral prophylaxis for kids with HAE.
BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of BioCryst Pharmaceuticals, Inc.'s Q1 2026 earnings call